ODYSSEY APPRISE trial evaluated efficacy and safety of alirocumab in 994 patients with hypercholesterolemia and high CV risk in a real-life setting. The aim of the present report is to detail on the Italian cohort enrolled and treated in the trial.
Cefalu', A.B., Garbelotto, R., Mombelli, G., Pirro, M., Rubba, P., Arca, M., et al. (2022). A subgroup analysis of the ODYSSEY APPRISE study: Safety and efficacy of alirocumab in the Italian cohort. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 32(11), 2638-2646 [10.1016/j.numecd.2022.07.020].
A subgroup analysis of the ODYSSEY APPRISE study: Safety and efficacy of alirocumab in the Italian cohort
Cefalu', Angelo B
Primo
Writing – Original Draft Preparation
;Averna, Maurizio
Ultimo
Supervision
2022-08-09
Abstract
ODYSSEY APPRISE trial evaluated efficacy and safety of alirocumab in 994 patients with hypercholesterolemia and high CV risk in a real-life setting. The aim of the present report is to detail on the Italian cohort enrolled and treated in the trial.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
A subgroup analysis of the ODYSSEY APPRISE study.pdf
accesso aperto
Descrizione: Articolo principale
Tipologia:
Versione Editoriale
Dimensione
691.44 kB
Formato
Adobe PDF
|
691.44 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
